Skip to content
Business
Prognosis

Oxford Vaccine Raises Hope for Second Malaria Shot Following GSK’s

  • New shot is found to maintain high efficacy after four doses
  • WHO recently formally endorsed first malaria vaccine from GSK
A mosquito seen through a microscope in the entomology laboratory at the National Center for research and training on malaria in Burkina Faso.

A mosquito seen through a microscope in the entomology laboratory at the National Center for research and training on malaria in Burkina Faso.

Photographer: Olympia de Maismont/AFP/Getty Images

Updated on

A malaria shot developed by researchers at the University of Oxford has shown that its strong protection can hold up a year after a booster, bolstering the case for a second vaccine to be used to protect children and infants in Africa from the deadly disease.

The vaccine, known as R21, was shown to have an efficacy as high as 80% one year after a fourth dose was administered to some 400 infants aged 5 to 17 months in an African region with seasonal circulation of the disease, according to a study published Wednesday by the peer-reviewed medical journal Lancet Infectious Diseases.